Spots Global Cancer Trial Database for A Multiple Myeloma Trial in Patients With Bone Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Multiple Myeloma Trial in Patients With Bone Metastases
Official Title: A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases
Study ID: NCT00104104
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to study the safety of treating patients with multiple myeloma and at least one bone lesion with zoledronic acid 4mg intravenously (IV) every 3 - 4 weeks for 2 years. Patients will receive a zoledronic acid infusion for 15 minutes or 30 minutes.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hematology Oncology Specialists, Huntsville, Alabama, United States
Palo Verde Hematology Oncology, Glendale, Arizona, United States
US Oncology, Tucson, Arizona, United States
Myeloma Institute For Research Therapy, Little Rock, Arkansas, United States
University of Arkansas, Little Rock, Arkansas, United States
Pacific Cancer Medical Center, Anaheim, California, United States
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Southbay Oncology Hematology Partners, Campbell, California, United States
Bay Area Cancer Research Group, Concord, California, United States
California Oncology of the Central Valley, Fresno, California, United States
Dr. Robert P. Brouillard Inc., LaJolla, California, United States
Antelope Valley Cancer Center, Lancaster, California, United States
Pacific Shores Medical Group, Long Beach, California, United States
North Valley H/O, Mission Hills, California, United States
Hematology/Oncology Group of Orange County, Orange, California, United States
Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States
Camino Medical Group, Sunnyvale, California, United States
Oncotherapeutics, West Hollywood, California, United States
Greeley Medical Center, Greeley, Colorado, United States
Florida Cancer Specialists, Fort Meyers, Florida, United States
South Florida Oncology Hematology, Hollywood, Florida, United States
Osceola Cancer Center, Kissimmee, Florida, United States
Miami Cancer Care, Miami, Florida, United States
Pasco Hernado Oncology, New Port Richey, Florida, United States
MetCare Oncology, Ormond Beach, Florida, United States
Hematology Oncology Associates PA, Pensacola, Florida, United States
Hem/Onc Associates of Central Brevard, Rockledge, Florida, United States
Augusta Oncology Associates, Augusta, Georgia, United States
Georgia Cancer Specialists, Tucker, Georgia, United States
Cancer Care Center, New Albany, Indiana, United States
Hutchinson Clinic, PA, Hutchinson, Kansas, United States
Hematology and Oncology Specialists, New Orleans, Louisiana, United States
Maine Center for Cancer Medicine - Blood Disorders, Scarborough, Maine, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Oncology Hematology Associates, PA, Clinton, Maryland, United States
Maryland Oncology-Hematology PA, Columbia, Maryland, United States
Hematology Oncology Associates of Ohio & Michigan, Lambertville, Michigan, United States
Providence Cancer Center, Clinical Trials Dept, Southfield, Michigan, United States
Kansas City Cancer Center, Kansas City, Missouri, United States
St. Joseph Oncology, Inc., St. Joseph, Missouri, United States
The Center for Cancer Care and Research, St. Louis, Missouri, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Nevada Cancer Center, Las Vegas, Nevada, United States
Center for Cancer & Hematology Disease, Cherry Hill, New Jersey, United States
Central Jersey Oncology Center, East Brunswick, New Jersey, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
CINJ at Cooper University Hospital, Voorhees, New Jersey, United States
New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States
Hematology Oncology of Western Suffolk, Bay Shore, New York, United States
New York Presbyterian Hospital, New York, New York, United States
Syracuse Hematology/Oncology PC, Syracuse, New York, United States
Dayton Oncology & Hematology, PA, Kettering, Ohio, United States
University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States
Pennsylvania Oncology Associates, Philadelphia, Pennsylvania, United States
Berks Oncology and Hematology Associates, West Reading, Pennsylvania, United States
Hematology & Oncology Associates of RI, Cranston, Rhode Island, United States
Roger Williams Hospital Medical Center, Providence, Rhode Island, United States
Charleston Hematology Oncology, Charleston, South Carolina, United States
Baptist Regional Cancer Center, Knoxville, Tennessee, United States
Center for Oncology Research & Treatment, PA, Dallas, Texas, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States
Utah Hematology Oncology, Ogden, Utah, United States
Oncology Hematology Associates of Southwest VA, Salem, Virginia, United States
Western Washington Oncology, Lacey, Washington, United States
Swedish Cancer Institute, Seattle, Washington, United States
Fox Valley Hematology Oncology SC, Appleton, Wisconsin, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
